Home Alzheimer’s Disease FDA Approves Umbralisib for Patients with Previously Treated MZL & FL

FDA Approves Umbralisib for Patients with Previously Treated MZL & FL

The FDA has granted accelerated approval to the once-daily, oral, dual inhibitor of PI3K-d and CK1-epsilon, umbralisib (Ukoniq), as a treatment for patients with previously treated marginal zone lymphoma (MZL) who have received at least 1 prior anti-CD20 based regimen or follicular lymphoma (FL) after at least 3 prior systemic therapies, announced the drug’s developer, TG Therapeutics.1

The FDA recommended dose of umbralisib is 800 mg taken orally once daily with food until disease progression or unacceptable toxicity.

The approval was primarily based on data from the MZL and FL patient cohorts of the global, multicenter, open-label phase 2b UNITY-NHL trial (NCT02793583).2 The MZL cohort was designed to evaluate the safety and efficacy of single-agent umbralisib in patients with MZL who have received at least 1 prior anti-CD20 regimen. The FL cohort was designed to evaluate the…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Recent Comments